ProPhase Labs, Inc. (PRPH) Stock
PRPH Key Statistics
About ProPhase Labs, Inc.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
CEO: Ted William Karkus. Company website
PRPH — Frequently Asked Questions
What is the PRPH stock price today?
ProPhase Labs, Inc. (PRPH) trades at $0.11, up 37.50% on the day, as of Sep 20, 2026 14:59 UTC.
What is ProPhase Labs, Inc.'s market cap?
ProPhase Labs, Inc. has a market capitalisation of $521,070.77, calculated from the live PRPH share price and shares outstanding.
What is the P/E ratio of PRPH?
PRPH has no meaningful price-to-earnings ratio: ProPhase Labs, Inc. lost $16.40 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does ProPhase Labs, Inc. make?
ProPhase Labs, Inc. generated revenue of $1.08M over the trailing twelve months, which puts the stock at 0.48 times sales.
What is the 52-week range for PRPH?
PRPH has traded between $0.07 and $0.19 over the past 52 weeks, and the last price is 42.1% below that high.
Is ProPhase Labs, Inc. profitable?
No. ProPhase Labs, Inc. is loss-making, with a net margin of -3,872.24% over the trailing twelve months.
What is the analyst price target for PRPH?
Wall Street analysts rate PRPH Buy, with an average price target of $140.00, 127,172.7% above the current price.
What sector is ProPhase Labs, Inc. in?
ProPhase Labs, Inc. is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US .
Who is the CEO of ProPhase Labs, Inc.?
Ted William Karkus is the chief executive of ProPhase Labs, Inc., which employs 96 people.
Where can I track PRPH in real time?
QFI Terminal shows PRPH with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PRPH live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PRPH in Terminal See plans